Clinical Trials Logo
  1. Home
  2. Lymphoid Malignancies
  3. NCT01013818

A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Lymphoid Malignancies Clinical Trial

Official title:
A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Clinical Trial Summary

The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01013818
Study type Interventional
Source Human Genome Sciences Inc.
Contact
Status Terminated
Phase Phase 1
Start date October 2009
Completion date October 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00383994 - Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation Phase 1
Recruiting NCT04329728 - The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies Phase 1/Phase 2
Terminated NCT01998035 - Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT01705847 - A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies Phase 1
Completed NCT00406809 - A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies Phase 1/Phase 2
Terminated NCT02739360 - Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 Phase 4
Terminated NCT00992732 - Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders Phase 2
Active, not recruiting NCT02452697 - Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT Phase 2
Not yet recruiting NCT06047886 - CD34 Selection Using the Automated CliniMACS Prodigy Phase 1
Completed NCT02181478 - Intra-Osseous Co-Transplant of UCB and hMSC Early Phase 1
Terminated NCT01596127 - Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System Phase 1/Phase 2
Completed NCT00820508 - Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies Phase 1
Recruiting NCT05371054 - Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00529438 - RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies Phase 1
Completed NCT01435447 - Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies Phase 2
Completed NCT00508807 - RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies Phase 1
Completed NCT02091063 - ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2